Characterization of a new human melanoma cell line with CD133 expression

Human Cell

Volumn 25, Issue 2, 2012, Pages 61-67

  Gil Benso, Rosario ^a   Monteagudo, Carlos ^a,b   Cerdá Nicolás, Miguel ^a,b   Callaghan, Robert C ^a,c   Pinto, Sandra ^c   Martínez Romero, Alicia ^c   Pellín Carcelén, Ana ^a   San Miguel, Teresa ^a   Cigudosa, Juan C ^d   López Ginés, Concha ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b Hospital Clinic   (Spain)

^c CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

^d Structural Biology and Biocomputing Programme   (Spain)

Author keywords

CD133; Cell line; Cytogenetics; Melanoma; Stem cells

Indexed keywords

B RAF KINASE; CD133 ANTIGEN; CD146 ANTIGEN; CD20 ANTIGEN; CD34 ANTIGEN; CD44V ANTIGEN; CD61 ANTIGEN; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; PROTEIN MDM2; PROTEIN P53; RAS PROTEIN; RETINOBLASTOMA BINDING PROTEIN; STEM CELL FACTOR RECEPTOR;

ADULT; ANEUPLOIDY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CARCINOGENICITY; CASE REPORT; CELL CYCLE REGULATION; CELL DEATH; CELL GROWTH; CELL POPULATION; CELL STRUCTURE; CLONING; CONTROLLED STUDY; CYTOGENETICS; DISTANT METASTASIS; FEMALE; FLOW CYTOMETRY; GENE AMPLIFICATION; GENE MUTATION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTRACRANIAL TUMOR; KARYOTYPE; KINETICS; LUNG; MALE; MEL RC08; MELANOMA; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; OCCIPITAL BONE; ONCOGENE C KIT; PLOIDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; ANTIGENS, CD; CELL CYCLE; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; MELANOMA; MUTATION; NEOPLASTIC STEM CELLS; PEPTIDES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT; SKIN NEOPLASMS;

EID: 84862135693     PISSN: 09147470     EISSN: 17490774     Source Type: Journal    
DOI: 10.1007/s13577-011-0027-y     Document Type: Article

References (32)

1. Ugurel S, Utikal J, Becker JC. Tumor biomarkers in melanoma. Cancer Control. 2009; 16: 219-24.
2. Mitelman F, Johansson B and Mertens F, editors. Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer (2010). http://cgap. nci. nih. gov/Chromosomes/Mitelman.
3. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417: 949-54.
4. Palmieri G, Capone M, Ascierto ML, et al. Main roads to melanoma. J Transl Med. 2009; 7: 86.
5. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006; 24: 4340-6.
6. Sabatino M, Stroncek DF, Klein H, Marincola FM, Wang E. Stem cells in melanoma development. Cancer Lett. 2009; 279: 119-25.
7. Boiko AD, Razorenova OV, van de Rijn M, et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature. 2010; 466: 133-7.
8. Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJ, Tahan SR. Increased expression of stem cell markers in malignant melanoma. Mod Pathol. 2007; 20: 102-7.
9. Rappa G, Fodstad O, Lorico A. The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells. 2008; 26: 3008-17.
10. Al Dhaybi R, Sartelet H, Powell J, Kokta V. Expression of CD133+ cancer stem cells in childhood malignant melanoma and its correlation with metastasis. Mod Pathol. 2010; 23: 376-80.
11. Monzani E, Facchetti F, Galmozzi E, et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer. 2007; 43: 935-46.
12. Gil-Benso R, Lopez-Gines C, López-Guerrero JA, et al. Establishment and characterization of a continuous human chondrosarcoma cell line, ch-2879: comparative histologic and genetic studies with its tumor of origin. Lab Invest. 2003; 83: 877-87.
13. ISCN (2005) In: Shaffer G, Tommerup N, editors. An international system for human cytogenetic nomenclature. Basel: Karger.
14. Greene VR, Johnson MM, Grimm EA, Ellerhorst JA. Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma. J Invest Dermatol. 2009; 129: 1483-8.
15. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996; 93: 9821-6.
16. Carless MA, Griffiths LR. Cytogenetics of melanoma and nonmelanoma skin cancer. Adv Exp Med Biol. 2008; 624: 227-40.
17. Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med. 2006; 355: 51-65.
18. Houben R, Becker JC, Kappel A, et al. Constitutive activation of the Ras-Raf signalling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog. 2004; 3: 6-8.
19. Patton EE, Widlund HR, Kutok JL, et al. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol. 2005; 15: 249-54.
20. Fang D, Nguyen TK, Leishear K, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 2005; 65: 9328-37.
21. Grichnik JM, Burch JA, Schulteis RD, et al. Melanoma, a tumor based on a mutant stem cell? J Invest Dermatol. 2006; 126: 1214-6.
22. Bongiorno MR, Doukaki S, Malleo F, Aricò M. Identification of progenitor cancer stem cell in lentigo maligna melanoma. Dermatol Ther. 2008; Suppl 1: 1-5.
23. Roesch A, Fukunaga-Kalabis M, Schmidt EC, et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell. 2010; 141: 583-94.
24. Bunting KD. Cells ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells. 2002; 20: 11-20.
25. Keshet GI, Goldstein I, Itzhaki O, et al. MDR1 expression identifies human melanoma stem cells. Biochem Biophys Res Commun. 2008; 368: 930-6.
26. Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating human melanomas. Nature. 2008; 451: 345-9.
27. Mizrak D, Brittan M, Alison MR. CD133: molecule of the moment. J Pathol. 2008; 214: 3-9.
28. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature. 2008; 456: 593-8.
29. Dietrich A, Tanczos E, Vanscheidt W, Schöpf E, Simon JC. High CD44 surface expression on primary tumours of malignant melanoma correlates with increased metastatic risk and reduced survival. Eur J Cancer. 1997; 33: 926-30.
30. Seftor RE. Role of the beta3 integrin subunit in human primary melanoma progression: multifunctional activities associated with alpha(v)beta3 integrin expression. Am J Pathol. 1998; 153: 1347-51.
31. Ouhtit A, Gaur RL, Abd Elmageed ZY, et al. Towards understanding the mode of action of the multifaceted cell adhesion receptor CD146. Biochim Biophys Acta. 2009; 1795: 130-6.
32. Garrido MC, Bastian BC. KIT as a therapeutic target in melanoma. J Invest Dermatol. 2010; 130: 20-7.